TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Jan 20, 2022
(A Top Pick Sep 24/20, Up 51.5%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend tailing up the stop (from $42) to $46.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$54.05

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 12, 2022
One of the world's largest biopharma companies. Expected revenue of 97B USD this year. Likes it because of its rapidly improving pipeline, especially the cardio drug. Vaccine will produce cashflow windfalls over the near term, plus lots of runway. Continuing shots needed, anti-viral pill will be in high demand. Good valuation. Yield is 2.86%, expected to grow. (Analysts’ price target is $56.61)
Photo of Stan WongStan Wong
Owned
Unlock Rating
$56.59

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 06, 2022
Leadership position in vaccine fight. If you invest here, and pandemic goes away, PFE's fortunes could regress to the mean. It won't have the wind at its back anymore. The uncertainty makes him pass.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$55.34

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 08, 2021
He stays away from drug companies, always forced to do acquisitions. Costly and competitive business. Pressures from government. Boost from pandemic, and this will continue. Reasonable valuation. He prefers medical devices, where you don't need a PhD to understand what's coming next. Attractive yield about 3%.
Photo of John O'Connell, CFAJohn O'Connell, CFA
No
Unlock Rating
$51.31

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 03, 2021
Among the vaccine stocks, he feels safe with this. They're coming out with their Covid pill treatment.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$54.27

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 22, 2021
Don't sell. Incredibly low valuation. Well positioned, well diversified. Established distribution network. Great long-term growth story over time.
Photo of John ZechnerJohn ZechnerUnlock Rating
$51.34

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Oct 29, 2021
They face a patent cliff in 2022, so will the Covid booster cover this? They report Tuesday.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$43.74

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 28, 2021
Has tended to peak out at 4x book value, around $50. Vaccine potential has petered out. FMV potential is 55% higher than current price. More likely to have a further setback, with $37-38 as his downside target. The stock's already given at the office and it's not prepared to give at home.
Photo of Ross HealyRoss HealyUnlock Rating
$43.14

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 18, 2021
All healthcare stocks have been pressured. PFE is protected by their near-4% dividend. We will all need their Covid booster shot.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$41.32

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Oct 04, 2021
The performance has been disappointing. The problem with big, old pharma is that it is not enough to move the needle. He thinks it is a good one to put away. They are a little constrained on the new product side. He'd suggest an ETF of biotech companies.
Photo of John ZechnerJohn ZechnerUnlock Rating
$42.42

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 30, 2021
Great dividend yield, not trading at a high multiple. Not a pure play. Covid vaccine issue will continue for years to come. Likes healthcare, but it tends to come up as a US political issue. A great story here. He owns JNJ instead.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$43.44

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Sep 22, 2021
Good quality stock that won't hurt you. Reasonable valuation, nice dividend. Bad news is everything is already built into the stock. Where's the growth past 2023? Not much upside. He'd add at $32-36, but not here at $44.
Photo of Greg NewmanGreg NewmanUnlock Rating
$44.27

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 17, 2021
A broad company with many types of drugs. Laws in the US stipulates that after spending millions of dollar for franchises, the drug will go off patent in time. Pharmaceuticals have been doing this for a long time.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$43.89

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 13, 2021
It looks good it will get FDA approval for a Covid vaccine for children. Any good news here will help PFE. He's owned this for a while. The current pullback is a buying opportunity.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$44.35

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2021

Many reasons to like this including booster shots which will help shares (though Moderna will benefit more). This has pulled back a but, she likes it here. Has value.

Photo of Karen FinermanKaren FinermanUnlock Rating
$46.04

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 166 to 180 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like